GRTX
Galera Therapeutics, Inc.Company with tickers: GRTX
Income-statement, balance-sheet and cash-flow figures extracted from the company's SEC filings — 10-K annual and 10-Q quarterly reports — and standardised for comparison across periods.
| Line Item | Value | Unit | Period End | Form | Filed |
|---|---|---|---|---|---|
| Revenue | — | ||||
| Revenue (ASC 606) | — | ||||
| Cost of Revenue | — | ||||
| Gross Profit | — | ||||
| Operating Expenses | — | ||||
| Research & Development | $15,000 | USD | 2026-03-31 | 10-Q | 2026-05-14 |
| Operating Income | $-1,655,000 | USD | 2026-03-31 | 10-Q | 2026-05-14 |
| Net Income | $-1,606,000 | USD | 2026-03-31 | 10-Q | 2026-05-14 |
| EPS (Basic) | $-0.01 | USD/shares | 2026-03-31 | 10-Q | 2026-05-14 |
| EPS (Diluted) | $-0.01 | USD/shares | 2026-03-31 | 10-Q | 2026-05-14 |